CA4 and ovarian carcinoma: Another CA-4 analogue ombrabulin/AVE8062 (85, Figure 13) (Table 2) marketed by Sanofi Aventis with superior solubility and oral bioavailability in comparison to CA-4 has been trialled Ombrabulin/AVE8062 in Phase 2 clinical studies for the treatment of ovarian carcinoma.